Lintuzumab-Ac225 plus CLAG-M shows promising efficacy in R/R AML
Lintuzumab-Ac225 plus CLAG-M yielded “deep and meaningful responses” in patients with relapsed/refractory acute myeloid leukemia (AML), according the results of a phase 1
Leukemia
Acute Myeloid Leukemia
News
Roundtable Discussions
MDS Roundtable
What is the patient journey for those undergoing blood transfusions?
In this roundtable discussion on anemia management in MDS, the panel discusses the journey of a patient undergoing blood transfusions.
Roundtable Discussions
MPN Roundtable
Can anemia agents improve outcomes with ruxolitinib in MPN?
In this video clip, the panel discusses the RR6 model's ability to predict outcomes for patients treated with ruxolitinib, particularly identifying those who
News
Roundtable Discussions
MPN Roundtable
Are there MPN therapies that improve platelets?
In this video segment of the MPN roundtable, the panel addresses common misconceptions about pacritinib, clarifying that while it enables JAK inhibition in
News
Roundtable Discussions
MPN Roundtable
Should luspatercept be used to treat myelofibrosis?
A roundtable discussion on anemia management in myeloproliferative neoplasms, featuring moderator John Mascarenhas, MD, Mount Sinai; Andrew Kuykendall, MD, Moffitt Cancer Center; and
News
Roundtable Discussions
MPN Roundtable
To add or switch therapy in MPN anemia?
Anemia remains a major challenge in the treatment of myeloproliferative neoplasms, especially for patients receiving ruxolitinib. In this expert roundtable, featuring moderator John
Meetings / Conferences
66th American Society of Hematology Annual Meeting & Exposition
Roundtable Discussions
MDS Roundtable
What’s changing in how we treat transfusion dependence in anemia?
In this segment of the MDS roundtable on anemia in lower-risk MDS, the panel, led by Guillermo Garcia-Manero discuss transfusion dependence.
66th American Society of Hematology Annual Meeting & Exposition
MDS
Roundtable Discussions
MDS Roundtable
What do the recent long-term COMMANDS data show?
Dr. Guillermo Garcia-Manero and the panel discuss long-term data from the COMMANDS trial in lower-risk MDS.
Meetings / Conferences
66th American Society of Hematology Annual Meeting & Exposition
News
Roundtable Discussions
MDS Roundtable
What are second line treatments in lower-risk MDS with anemia?
A roundtable discussion on anemia management in myelodysplastic syndromes, featuring moderator Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center;
Meetings / Conferences
66th American Society of Hematology Annual Meeting & Exposition
Roundtable Discussions
MDS Roundtable
How do you treat patients with MDS and anemia?
A roundtable discussion on anemia management in myelodysplastic syndromes (MDS), featuring moderator Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center;